E
Eddy Anglade
Researcher at Astellas Pharma
Publications - 4
Citations - 1158
Eddy Anglade is an academic researcher from Astellas Pharma. The author has contributed to research in topics: Macular degeneration & Visual acuity. The author has an hindex of 3, co-authored 3 publications receiving 1011 citations. Previous affiliations of Eddy Anglade include Advanced Cell Technology.
Papers
More filters
Journal ArticleDOI
Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies
Steven D. Schwartz,Carl D. Regillo,Byron L. Lam,Dean Eliott,Philip J. Rosenfeld,Ninel Z. Gregori,Jean-Pierre Hubschman,Janet L. Davis,Gad Heilwell,Marc J. Spirn,Joseph I. Maguire,Jane Bateman,Rosaleen Ostrick,Debra Morris,Matthew Vincent,Eddy Anglade,Lucian V. Del Priore,Robert Lanza +17 more
TL;DR: The results suggest that hESC-derived cells could provide a potentially safe new source of cells for the treatment of various unmet medical disorders requiring tissue repair or replacement.
Journal ArticleDOI
Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration
Manjit S Mehat,Venki Sundaram,Caterina Ripamonti,Anthony G. Robson,Alexander J. Smith,Shyamanga Borooah,Martha Robinson,Adam N. Rosenthal,William Innes,Richard G. Weleber,Richard W J Lee,Michael D. Crossland,Gary S. Rubin,Baljean Dhillon,David H. W. Steel,Eddy Anglade,Robert Lanza,Robin R. Ali,Michel Michaelides,James W B Bainbridge +19 more
TL;DR: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence, and intervention in early stage of disease should be approached with caution.
Journal ArticleDOI
Stem cells in age-related macular degeneration and Stargardt's macular dystrophy - Authors' reply.
TL;DR: Although the subretinal area is privileged, researches have shown that the transplanted cells in the host eye still need long-term immune suppression for survival, and the duration of immunosuppression and the recommended dose remains to be discussed in detail.
Journal ArticleDOI
First-in-Human Gene Therapy Trial of AAV8-hCARp.hCNGB3 in Adults and Children with CNGB3-associated Achromatopsia.
Michel Michaelides,Nashila Hirji,Sui Wong,Cagri G. Besirli,Serena Zaman,Neruban Kumaran,Anastasios Georgiadis,Alexander J. Smith,Caterina Ripamonti,Irene Gottlob,A. Robson,Alberta A H J Thiadens,Robert H. Henderson,Penny R. Fleck,Eddy Anglade,Xiangwen Dong,George Capuano,Wentao Lu,Pamela Berry,Thomas Kane,Stuart Naylor,Michalis Georgiou,Angelos Kalitzeos,Robin R. Ali,Alexandra Lindsay Forbes,James W B Bainbridge +25 more
TL;DR: In this paper , the authors evaluated the safety and efficacy of AAV8-hCARp.hCNGB3 in participants with CNGB3-associated achromatopsia (ACHM).